APAC Vaccine Contract Manufacturing Market

Asia Pacific Vaccine Contract Manufacturing Market Size (2022 to 2027)

The size of the Vaccine contract manufacturing market in APAC was about USD 225.09 million in 2022. It is expected to rise at a CAGR of 9.8% and go up to USD 359.23 million by 2027. The main reason behind it is speculated to be research advancements and an increase in population. Also, there has been increasing in the trend of mergers and acquisitions in the region, leading to a broad spectrum of organizations.

The biopharmaceutical contract manufacturing market in the Asia Pacific is expected to grow due to the growth of the biopharmaceutical sector in China and India. In addition, increased disposable income, combined with government commitments to promote improved access to essential healthcare services, boosts the availability and affordability of medicines for millions of more people. As a result, multinational pharmaceutical corporations will be keen to obtain access to Asia-Pacific countries and invest in infrastructure development, which is estimated to favor the vaccine contract manufacturing market in the APAC region.

Additionally, the market's growth is further expected to be driven by factors such as the growing population, improved access to medications. Furthermore, economic gains and rising incomes, particularly among low-income earners, in the fast-growing pharmerging economies, including China, are expected to be a plus to the market's growth rate.

Due to the rise in infectious diseases and the emergence of endemics and pandemics worldwide, there has been a strong demand for contract manufacturing services. Furthermore, because of the growing focus on preventing deaths caused by vaccine-preventable diseases, Asia Pacific is expected to contribute the most income to the commercial vaccine industry. In addition, the emergence of the RNA platform has hastened the creation of vaccines.

However, a high degree of knowledge and long-term experience is required to manufacture parenteral pharmaceuticals successfully. This is due to the compounds complex composition as well as their complicated handling needs. Therefore, the normal cost-cutting feature seen in other manufacturing services, which is often a significant benefit of goods manufactured in the Asia Pacific, has less impact on Injectables. However, challenges with factory setups and vaccine production impede the growth of the vaccine contract manufacturing market in the APAC region. In addition, vaccination costs and patent expiration could have a negative impact on market growth throughout the forecast period.

Strict regulatory limitations, combined with high cost, production, and advancements-related roadblocks, have resulted in insufficient competition between vaccine manufacturers, further estimated to hamper the market’s growth rate.

This research report on the APAC vaccine contract manufacturing market has been segmented and sub-segmented into the following categories:

By Service Type:

• Bulk Product
• Fill Finish

By Product Type:

• Single Vaccine
  • Influenza Virus
  • Ebola Virus
  • Chickenpox
  • Tetanus
  • Tuberculosis
  • Polio
  • Smallpox
  • Others
• Combination Type

By Vaccine Type:

• Inactivated Vaccines
• Conjugate Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vector Vaccines
• Subunit Vaccines
• Synthetic Vaccines

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

One of the fastest expanding regions for vaccine contract manufacturing across the globe is the Asia Pacific, and contract manufacturers in the region are benefiting from the growing trend of outsourcing. Vaccine production regulations, particularly in India, China, and Japan, are encouraging market growth. In addition, the rising prevalence of infectious diseases and the rising number of fatalities from vaccine-preventable diseases have boosted the demand for vaccines.

The growing older population, the prevalence of bacterial and viral illnesses, the demand for novel vaccines, and the burgeoning biopharma and biotech industries contribute to the rise of contract manufacturing in the Asia-Pacific area. APAC is seeing rising market demand, owing to a significant and growing population that enhances vaccine access. In addition, various prospects connected with an increasing vaccine pipeline increased the outsourcing of vaccine manufacturing services. The introduction of unique and innovative technologies is projected to significantly impact the future of the vaccine contract manufacturing market in APAC.

Over the last few years, the APAC area has seen a lot of pharmaceutical contract manufacturing. We've seen a significant transformation in the kind and manner of contract manufacturing and how drug goods are supplied over this time. Consider that formerly, medicines manufactured in the region were also primarily designed for usage within the APAC countries.

KEY MARKET PLAYERS:

A few of the notable companies operating in the Asia Pacific vaccine contract manufacturing market include Merck, Baxter International, Crucell, Sanofi Pasteur, Emergent BioSolutions, Novartis, Bavarian Nordic A/S, Pfizer Inc, Sinovac Biotech, Ltd, and GlaxoSmithKline.